Epidermal growth factor enhances MPC-83 pancreatic cancer cell migration through the upregulation of aquaporin 3.

Aquaporin (AQP) water channels are expressed in high-grade tumor cells of different tissue origins. In this study, we investigated whether AQP3 is expressed in cultured MPC-83 pancreatic cancer cells, whether AQP3 enhances cell migration and the signal pathway mechanism involved. MPC-83 pancreatic cancer cells were pre-treated and treated with EGF at different time points and then analyzed using western blotting. Results showed that epidermal growth factor (EGF) induced the phosphorylation of the EGF receptor (EGFR) and extracellular signal-regulated kinase (ERK), which peaked at 5 min after EGF treatment. EGFR and ERK phosphorylation induced by EGF were inhibited by PD153035 (EGFR tyrosine kinase inhibitor) and U0126 (ERK inhibitor), respectively. EGF increased the activity of AQP3 in a dose- and time-dependent manner in MPC-83 pancreatic cancer cells, which peaked at 24 h after treatment. The activity of AQP3 and cell migration were inhibited by PD153035, U0126 and CuSO4 (AQP3 water transport inhibitor). EGFR/ERK pathway-mediated AQP3 activation and cell migration were stimulated by EGF in cultured MPC-83 pancreatic cancer cells in vitro and this cell signaling pathway is inhibited by the EGFR and ERK inhibitors, which may be used as potential therapeutic targets in the treatment of pancreatic cancer.

[1]  B. Carr,et al.  Cell membrane and cytoplasmic epidermal growth factor receptor expression in pancreatic ductal adenocarcinoma , 2012, Medical Oncology.

[2]  D. Ribatti,et al.  Role of aquaporins in cell migration and edema formation in human brain tumors. , 2011, Experimental cell research.

[3]  Yi-Song Wang,et al.  Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors. , 2011, Cancer treatment reviews.

[4]  Stephen L. Abrams,et al.  Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy , 2011, Leukemia.

[5]  A. Bardelli,et al.  Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer , 2010, Targeted Oncology.

[6]  C. Campen,et al.  Anti-EGFR-Targeted Therapy for Esophageal and Gastric Cancers: An Evolving Concept , 2009, Journal of oncology.

[7]  A. Engel,et al.  The AQP structure and functional implications. , 2009, Handbook of experimental pharmacology.

[8]  M. Caruso,et al.  EGFR-targeted therapy in colorectal cancer: does immunohistochemistry deserve a role in predicting the response to cetuximab? , 2008, Current opinion in molecular therapeutics.

[9]  M. Papadopoulos,et al.  Aquaporins—new players in cancer biology , 2008, Journal of Molecular Medicine.

[10]  M. Papadopoulos,et al.  Aquaporins and cell migration , 2008, Pflügers Archiv - European Journal of Physiology.

[11]  D. Arpin,et al.  [Tyrosine kinase inhibitors in the management of non-small cell lung cancer]. , 2007, Revue des maladies respiratoires.

[12]  Sugunavathi Sepramaniam,et al.  Aquaporins: a promising target for drug development , 2006, Expert opinion on therapeutic targets.